‘Best I've ever used' say Amazon shoppers as La Roche-Posay over-make-up SPF mist gets slashed to £10.50
The anti-shine sun screen spray costs £18.50 on other sites, but it's been slashed to £10.50 for a limited time in the Amazon sale.
La Roche-Posay Anthelios Invisible Anti-Shine Mist Sun Screen, £10.54 (was £18.50)
BUY HERE
As the temperatures are set to soar in the UK this week, finding a good SPF is essential for the face is essential.
La Roche's Anthelios Sun Screen Spray is made with popular skincare ingredient glycerin for hydration and airlicium for shine control.
The lightweight, invisible consistency means it can be applied over make-up without leaving a white cast, which is a game-changer for sunny days out and holidays.
Designed specifically for oily skin, the face mist works to protect the skin without adding shine or causing breakouts.
La Roche-Posay has described the sun screen as having, "high protection with the lightness and freshness of a thermal spring water."
The spray could also be applied to the hairline for added sun protection without adding oil to the scalp.
Hundreds of Amazon shoppers have given the £11 SPF a five-star rating online.
One reviewer wrote: "I normally hate applying sun cream but this is the next generation, it works brilliantly.
It's expensive when it's not on offer, but it's the best I've ever used.
If you want a sun cream that feels like a water spray, this is for you."
Another added: "This is my first choice when it comes to sunscreen, I use it regularly and it is gentle on my skin.
I have been using this product for years and my skin is prone to rashes and irritation but with I've never had any issues with this product."
La Roche-Posay's Anthelios Ultra-Light Invisible Fluid Sun Screen, £12.56 (was £19.57)
BUY HERE
La Roche-Posay's Anthelios Ultra-Light Sun Screen has also been reduced in the Amazon sale.
The viral buy has been slashed from £20 to £12.56, so beauty fans can save an impressive £36.
Designed for sensitive skin, the cream creates a light veil for protection in the sun — and it's also sweat and sand-resistant.
For a more detailed review of the La Roche SPF, you can read Sun Shopping's tried-and-tested roundup of the best face SPFs.
We've also put some of the best sun creams on the market to the test in preparation for the heatwave.
Amazon has been treating shoppers to reduced heatwave beauty essentials in recent weeks, including the viral Garnier tanning drops that are currently on sale.
Mrs Hinch is even known to be a fan of the budget buy.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sky News
27 minutes ago
- Sky News
New NHS bladder cancer treatment doubles survival time
The NHS will roll out a new treatment for advanced bladder cancer which doubles survival time. It's estimated that 1,250 people a year could benefit from a combination of drugs called enfortumab vedotin and pembrolizumab. The first is an antibody-drug also known as Padcev, made by Astellas and Pfizer, while the latter is a PD-L1 inhibitor, also known as Keytruda, which is made by Merck. Clinical trials suggest the combo leads to improved survival compared to platinum-based chemotherapy - increasing from an average of around 16 months to almost 34. Researchers also found people survive for longer without their disease worsening, also known as progression-free survival - going up from six months to more than a year. It will mark the first significant change to treatment of advanced bladder cancer since the 1980s, according to expert Professor Thomas Powels, director of Barts Cancer Institute Biomedical Research Centre (QMUL). Around 18,000 people in England are diagnosed with bladder cancer each year. The new treatment was approved for NHS use by the National Institute for Health and Care Excellence, which said it was "highly promising" and could make a "tremendous difference" to people. One patient who took part in the trial said it had given him more time with his grandson. Martyn Hewett, 75, from Stratford, east London, said: "I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. "I am going to have an extra few years to see my grandson grow up - and maybe even be around to see him get married."
The Independent
an hour ago
- The Independent
Blood matching test to be offered to patients with rare conditions
The health service has launched a personalised 'blood matching' test for people with rare conditions who require regular blood transfusions. The move will allow donor blood to be matched to these patients more closely, to reduce the risk of severe reactions. The new test uses genetics to generate detailed blood group information. It is the first time it has been used for patients with rare inherited anaemias – with around 300 people eligible for testing, according to NHS Blood and Transplant (NHSBT). The programme has been backed by the family of toddler Woody Mayers, aged 22 months, who has a rare inherited anaemia called congenital dyserythropoietic anaemia (CDA) type 1. The condition causes the bone marrow to struggle to produce healthy red blood cells, which carry oxygen around the body. It is estimated to affect between one to five out of every million babies. Patients have low haemoglobin levels, meaning Woody relies on blood transfusions every four weeks to stay alive. However, the donor blood must be carefully matched to reduce the risk of patient's developing antibodies against certain blood types, which can cause severe reactions and make transfusions more difficult in the future. The new genotyping testing programme, a partnership between NHSBT and NHS England, uses genetics to identify more of the rarer blood groups. Samples are collected at routine hospital appointments, with patients' DNA tested to find out their blood types. About 300 people with transfusion dependent, rare inherited anaemias, are eligible for the test. All patients with sickle cell disorder and thalassaemia are also eligible, even if they do not rely on blood transfusions. Kate Downes, head of genomics at NHSBT, said: 'The new genotyping test can test blood groups faster and more extensively than standard testing methods.' Professor Dame Sue Hill, chief scientific officer at NHS England, said: 'The power of genomics is transforming medicine, with extended blood group genotyping now being utilised to help patients, especially those requiring regular transfusions. 'This is an exceptional example of an evidence-based innovation, developed from genetic data, being used to drive forward improvements that will make a huge difference across the NHS. 'Blood donations can be lifesaving for patients, and the NHS needs a constant flow of donations to provide people with the best possible care, so I'd encourage anyone who can donate to do so.' Woody's family were alerted to potential health conditions at a 20-week pregnancy scan. He was born prematurely at 34 weeks with haemoglobin levels around a quarter of what they should have been. Woody's mother Polly Mayers, 35, from Robertsbridge in East Sussex, said: 'When he was born, he was very poorly and pale. He didn't cry for a few minutes. He needed ventilation breaths. It was really frightening. 'The first few days were very critical for Woody. He was extremely unwell. Nobody knew the cause for his haemolytic anaemia.' The toddler has now being having regular transfusions fore more than a year, receiving 140mls of red blood cells every four weeks to boost his haemoglobin. Despite this, his family describes him as an energetic little boys who likes trips to the park and riding his bike. His mother added: 'Woody will need the blood to be well-matched so that his transfusions don't become too difficult or risky. 'The test will help him and anyone else with a similar condition. I hope everyone eligible gets it.' Ms Downes said: 'Woody has very rare disorder and he relies on blood transfusions to stay alive but these need to be well matched. 'We want everyone eligible, like Woody, to be tested so they can get better matched blood. We also need more people to donate, so we can supply the matched lifesaving blood to Woody and people like him.' Woody's family are also urging people to donate blood. Mrs Mayers, a community matron, said: 'There's no way to sugar-coat it – if it wasn't for blood donors, Woody would not be alive. 'I'm incredibly grateful to blood donors for ensuring blood is available when he needs it.'
Times
2 hours ago
- Times
Is this a good time to buy shares in Convatec?
After a volatile year for shares in Convatec they received a welcome boost on Wednesday when the FTSE 100 medical equipment company launched a share buyback of up to $300 million. The programme, representing up to 5 per cent of Convatec's market capitalisation, will run until the end of the year. The return of surplus capital to shareholders lifted the shares 5.6 per cent, gaining 13p, to close at 244¼p on the London Stock Exchange, the session's biggest riser on the premier share index. The buyback, being handled by UBS, was received by the market as a sign of health in the outlook for Convatec, whose shares, which were up 30 per cent in the first half of the year, have de-rated since June on concerns about product reimbursement cuts in the United States, its largest market, where the Trump administration has launched an efficiency drive. Despite the stock having seemingly priced in the exposure, some investors have remained on the sidelines, concerned that changes to US federal reimbursement in chronic care and skin substitutes could hit Convatec's sales and forecasts more than expected. Convatec has quantified the potential impact. It guided at its half-year results at the end of July for a potential 1 per cent to 2 per cent headwind on its 2026 revenues and the same range in 2027. The company also reiterated its forecasts for the current financial year, of group organic revenue growth of between 5.5 per cent and 7 per cent. This excludes sales of at least $75 million from InnovaMatrix, a wound treatment whose sales are uncertain because of the prospect of a curtailment of Medicare coverage, a US health insurance scheme. Convatec also reiterated an adjusted operating margin between 22 per cent and 22.5 per cent for this year and said it remained on course to 'consistently deliver' medium-term targets of 5 per cent to 7 per cent organic revenue growth and to reach a 'mid-20s' percentage adjusted operating margin by 2026 or 2027. Sellside bulls argue that investors have overlooked Convatec's results. Uncertainty, though, increased this month when Convatec announced, in a brief statement, that Karim Bitar, its well-regarded chief executive, was taking an indefinite medical leave of absence from the company. He has been replaced by Jonny Mason, the chief financial officer, on an interim basis, and Fiona Ryder, the group financial controller, will in turn take Mason's place as chief financial officer in the interim. Since Bitar, 60, was parachuted in as chief executive by Novo Holdings, a top shareholder, in 2019, he has led the turnaround of the FTSE 100 company after a period of profit warnings and boardroom upheaval. Convatec, founded in 1978, employs about 10,000 people globally and operates in around 90 countries. The company's strategy centres on four chronic care categories — including ostomy and continence care — and prioritises 12 key markets, with the United States as its largest. Since 2019 revenue growth has risen from 2.3 per cent; Convatec has delivered six straight years of accelerating growth; its annual research and development expenditure has doubled to about $100 million; and it has replenished its pipeline of new products. Amid the US and leadership uncertainty, then, the share buyback has helped reinforce the bull case. The buyback was consistent with Convatec's capital allocation plans, under which it targets a 2 times net debt/ebitda leverage ratio. Analysts at UBS, Convatec's house broker, forecast a year-end ratio of 1.3 times, rising to 1.7 times following the buyback. The broker, which reiterated its 'buy' rating and 231p price target, believes Convatec has the cashflows for a consistent buyback programme, which excluding mergers and acquisitions, could return up to $2 billion, or one third of Convatec's existing market capitalisation over the next four years. Similarly, Berenberg told clients on Wednesday, before the buyback was announced, that the 20 per cent de-rating in Convatect's shares since June was a 'buying opportunity', with the company trading on a 16 times price-earnings ratio. Advice Buy Why Buyback underpins confident outlook and shares have de-rated since Tempus's recommendation in February
